Asset profile
INV-202
Small molecule
Evidence outlook · lead readout
NCT05891834 · Obesity, Metabolic Syndrome
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05891834: The study randomly assigned 243 participants to three INV-202 dose groups or placebo and used quadruple masking of participants, care providers, investigators, and outcome assessors. Its primary clinical endpoint was mean change in body weight at Week 16, but the comparison result has not been reported.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.